Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study

International Journal of Cardiology

Volumn 238, Issue , 2017, Pages 72-78

  Tseng, Wei Cheng ^a,b   Liu, Jia Sin ^d   Hung, Szu Chun ^c   Kuo, Ko Lin ^c   Chen, Yu Hsin ^b   Tarng, Der Cherng ^a,b   Hsu, Chih Cheng ^b,d,e  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c DALIN TZU CHI HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Advanced chronic kidney disease; Heart failure; Mortality; Spironolactone

Indexed keywords

SPIRONOLACTONE; DIURETIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERKALEMIA; LONGITUDINAL STUDY; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; CHEMICALLY INDUCED; EPIDEMIOLOGY; HEALTH SURVEY; MIDDLE AGED; PROCEDURES; TAIWAN; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MORTALITY; POPULATION SURVEILLANCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SPIRONOLACTONE; TAIWAN;

EID: 85016720201     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2017.03.080     Document Type: Article

References (39)

1. [1] Gansevoort, R.T., Correa-Rotter, R., Hemmelgarn, B.R., et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382 (2013), 339–352.
2. [2] Tomiyama, C., Higa, A., Dalboni, M.A., et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol. Dial. Transplant. 21 (2006), 2464–2471.
3. [3] C. Blood Pressure Lowering Treatment Trialists, Ninomiya, T., Perkovic, V., et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ, 347, 2013, f5680.
4. [4] Baigent, C., Landray, M.J., Reith, C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
5. [5] Palmer, S.C., Di Micco, L., Razavian, M., et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann. Intern. Med. 156 (2012), 445–459.
6. [6] Papademetriou, V., Lovato, L., Doumas, M., et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 87 (2015), 649–659.
7. [7] Epstein, M., Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease. Lancet Diabetes Endocrinol. 2 (2014), 925–927.
8. [8] Desai, A.S., Swedberg, K., McMurray, J.J., et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J. Am. Coll. Cardiol. 50 (2007), 1959–1966.
9. [9] Edwards, N.C., Ferro, C.J., Kirkwood, H., et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am. J. Cardiol. 106 (2010), 1505–1511.
10. [10] Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341 (1999), 709–717.
11. [11] Matsumoto, Y., Kageyama, S., Yakushigawa, T., et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology 114 (2009), 32–38.
12. [12] Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37 (2016), 2129–2200.
13. [13] Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 (2013), 1810–1852.
14. [14] Inampudi, C., Parvataneni, S., Morgan, C.J., et al. Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction < 45%, and estimated glomerular filtration rate < 45 ml/min/1.73 m(2.). Am. J. Cardiol. 114 (2014), 79–82.
15. [15] Hsu, T.W., Liu, J.S., Hung, S.C., et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern. Med. 174 (2014), 347–354.
16. [16] Hung, S.C., Chang, Y.K., Liu, J.S., et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 3 (2015), 605–614.
17. [17] Yang, H.Y., Chiu, W.C., Huang, J.H., Hsu, C.Y., Lin, Y.K., Chen, Y.J., Analysis of 10-year nationwide population-based data on sex differences in hospitalization for heart failure. Heart Vessel. 28 (2013), 721–727.
18. [18] Wu, C.Y., Chen, Y.J., Ho, H.J., et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308 (2012), 1906–1914.
19. [19] Beygui, F., Cayla, G., Roule, V., et al. Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial. J. Am. Coll. Cardiol. 67 (2016), 1917–1927.
20. [20] Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370 (2014), 1383–1392.
21. [21] Matsumoto, Y., Mori, Y., Kageyama, S., et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J. Am. Coll. Cardiol. 63 (2014), 528–536.
22. [22] Henger, A., Tutt, P., Riesen, W.F., Hulter, H.N., Krapf, R., Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients. J. Lab. Clin. Med. 136 (2000), 379–389.
23. [23] Cabrera, S.E., Edwards, N.C., Steeds, R.P., Townend, J.N., Ferro, C.J., Spironolactone increases serum uric acid levels in patients with chronic kidney disease. J. Hum. Hypertens. 28 (2014), 210–211.
24. [24] Garca Puig, J., Miranda, M.E., Mateos, F., Herrero, E., Lavilla, P., Gil, A., Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension. J. Clin. Pharmacol. 31 (1991), 455–461.
25. [25] Yamaji, M., Tsutamoto, T., Kawahara, C., et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure. Am. Heart J. 160 (2010), 915–921.
26. [26] Shavit, L., Lifschitz, M.D., Epstein, M., Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int. 81 (2012), 955–968.
27. [27] Jankowska, E.A., Biel, B., Majda, J., et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 114 (2006), 1829–1837.
28. [28] Sarafidis, P.A., Blacklock, R., Wood, E., et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin. J. Am. Soc. Nephrol. 7 (2012), 1234–1241.
29. [29] Hernandez, A.F., Mi, X., Hammill, B.G., et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA 308 (2012), 2097–2107.
30. [30] Pfeffer, M.A., Burdmann, E.A., Chen, C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361 (2009), 2019–2032.
31. [31] Skali, H., Parving, H.H., Parfrey, P.S., et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 124 (2011), 2903–2908.
32. [32] Johnson, L.A., Govani, S.M., Joyce, J.C., Waljee, A.K., Gillespie, B.W., Higgins, P.D., Spironolactone and colitis: increased mortality in rodents and in humans. Inflamm. Bowel Dis. 18 (2012), 1315–1324.
33. [33] Kato, Y., Kamiya, H., Koide, N., et al. Spironolactone inhibits production of proinflammatory mediators in response to lipopolysaccharide via inactivation of nuclear factor-kappaB. Immunopharmacol. Immunotoxicol. 36 (2014), 237–241.
34. [34] Botha, T., Ryffel, B., Reactivation of latent tuberculosis infection in TNF-deficient mice. J. Immunol. 171 (2003), 3110–3118.
35. [35] O'Brien, D.P., Briles, D.E., Szalai, A.J., Tu, A.H., Sanz, I., Nahm, M.H., Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect. Immun. 67 (1999), 595–601.
36. [36] Moore, T.A., Lau, H.Y., Cogen, A.L., Standiford, T.J., Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alpha. Clin. Infect. Dis. 41:Suppl. 3 (2005), S213–S217.
37. [37] Heiat, A., Gross, C.P., Krumholz, H.M., Representation of the elderly, women, and minorities in heart failure clinical trials. Arch. Intern. Med. 162 (2002), 1682–1688.
38. [38] McMurray, J.J., Adamopoulos, S., Anker, S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33 (2012), 1787–1847.
39. [39] Ma, M.H., Chiang, W.C., Ko, P.C., et al. Outcomes from out-of-hospital cardiac arrest in Metropolitan Taipei: does an advanced life support service make a difference?. Resuscitation 74 (2007), 461–469.